The pivotal pathogenic AD pathway involving beta-secretase and gamma- secretase |
|
|
|
|
|
|
The ongoing phase III trials of solanezumab, gantenerumab, and aducanumab and the ongoing phase II trials of crenezumab and BAN-2401 |
|
|
|
|
|
|
That the negative or marginal results from anti-amyloid trials to date may have been caused by wrong disease stage, a heterogeneous population, limited target engagement due to ARIA-related dose restrictions, and/or only a partial effect observed with monotherapy |
|
|
|
|
|
|
Potential for combination therapy with secretase inhibitors, anti-amyloid antibodies, anti-tau agents, and neuroprotective drugs |
|
|
|
|
|
|
That Alzheimer’s pathology, as defined by the presence of amyloid and tau on PET probably appears approximately 10 years before the illness |
|
|
|
|
|
|
That tau PET shows the presence of pathology even in younger individuals and that in normal elderly, between the ages of 65 and 85 years, the presence of tau on PET imaging correlates with worse memory performance |
|
|
|
|
|
|